On 11th December we were delighted to see publication in the journal Nature and widespread coverage on the BBC of the latest findings of the University of Edinburgh GenOMICC project which Sepsis Research financially supports.
Click here to read more.
The research has identified a number of genes – amongst them TYK2, DPP9, OAS and IFNAR2 – which when faulty lead to the excessive inflammatory response to infection in the body that characterises both COVID-19 and sepsis.
This discovery bodes well for the development of treatments for sepsis and COVID-19 via existing anti-inflammatory drug therapies such as those used for rheumatoid arthritis. It therefore represents a significant development in the global understanding of the diagnosis and treatment of both sepsis and COVID. In addition, following on from the prioritisation of the GenOMICC study by the National Institute for Health Research at the start of the pandemic, the Roslin Institute has now reached a landmark 10,000 DNA samples collected from patients in ICU’s. It is clear that the exponential increase in sample collection has pushed the study forward by years and that it is therefore even closer to its ultimate goal of 100,000 samples collected.
We are extremely grateful to the team at the Roslin Institute led by Dr Kenneth Baillie for the huge amounts of hard work that they have put into the research and into establishing these important findings.
See the latest update from Jason Leitch, National Clinical Director for Scotland below.